Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: Initial response and long-term follow-up

European Journal of Gynaecological Oncology

Volumn 27, Issue 6, 2006, Pages 603-606

  Ayhan, A ^a   Taskiran, C ^a,b   Yigit Celik, N ^a   Gultekin, M ^a   Tuncer, S ^a   Guler, N ^a   Yuce, K ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Ovarian cancer; Recurrence; Second line; Topotecan; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; LAPAROTOMY; LEUKOPENIA; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SECOND-LOOK SURGERY; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 33846491840     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. DiSaia P.J., Creasman W.T.: "Epithelial ovarian cancer". In: DiSaia P.J., Creasman W.T. (eds.). Clinical Gynecologic Oncology, Sixth Edition. Mosby Inc., 289.
2. Hsiang Y.H., Liu L.F.: "Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin". Cancer Res., 1988, 48, 1722.
3. Creemers G.J., Lund B., Verweij J.: "Topoisomerase I inhibitors: topotecan and irenotecan". Cancer Treat. Rev., 1994, 20, 73.
4. Creemers G.J., Bolis G., Gore M. et al.: "Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study". J. Clin. Oncol., 1996, 14, 3056.
5. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B., Fields S.Z.: "Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel". J. Clin. Oncol., 1998, 16, 3345.
6. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J.: "Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study". J. Clin. Oncol., 2000, 18, 1062.
7. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., Herzog T.J.: "Topotecan in platinum- and paclitaxel-resistant ovarian cancer". Gynecol. Oncol., 1997, 66, 480.
8. Kudelka A.P., Tresukosol D., Edwards C.L. et al.: "Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma". J. Clin. Oncol., 1996, 14, 1552.
9. Rodriguez M., Rose P.G.: "Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer". Gynecol. Oncol., 2001, 83, 257.
10. Hoskins P., Eisenhauer E., Beare S. et al.: "Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study". J. Clin. Oncol., 1998, 16, 2233.
11. th edition, St. Louis, Mosby Inc., 621.
12. th, edition. Philadelphia: Lippincott Williams & Wilkins, 2001, 2, 1597.
13. Ozols R.F.: "Update of the NCCN ovarian cancer practice guidelines". Oncology (Huntingt), 1997, 11, 95.
14. Malik I.A.: "An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country". Int. J. Gynecol. Cancer, 2000, 10, 443.
15. ten Bokkel Huinink W., Gore M., Carmichael J. et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oncol., 1997, 15, 2183.
16. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J. Clin. Oncol., 2001, 19, 3312.
17. Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z.: "Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients". Int. J. Oncol., 1999, 15, 1233.
18. Armstrong D., O'Reilly S.: "Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity". Oncologist, 1998, 3, 4.
19. Morris R., Munkarah A.: "Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer". Oncologist, 2002, 7 (suppl. 5), 29.
20. Morris R.T.: "Weekly topotecan in the management of ovarian cancer". Gynecol. Oncol., 2003, 90 (3 Pt 2), S34.